KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other financing activities (2023)

Biocryst Pharmaceuticals (BCRX) has disclosed Other financing activities for 5 consecutive years, with $262000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Other financing activities changed N/A year-over-year to $262000.0, compared with a TTM value of $262000.0 through Dec 2024, up 110.75%, and an annual FY2023 reading of $11.1 million, changed N/A over the prior year.
  • Other financing activities was $262000.0 for Q3 2023 at Biocryst Pharmaceuticals, up from -$1.2 million in the prior quarter.
  • Across five years, Other financing activities topped out at $262000.0 in Q3 2023 and bottomed at $262000.0 in Q3 2023.